NURIX THERAPEUTICS, INC. (NRIX) FY2026 YTD Q3 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2025-12-01 to 2026-08-31

Swipe to see the full flow
NURIX THERAPEUTICS, INC. cash flow reconciliation, Dec 1, 2025 through Aug 31, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income (loss) → Net cash from operating activities: $373,098,000.00Deferred collaboration funding → Operating adjustments reconciliation: $45,609,000.00Stock-based compensation → Operating adjustments reconciliation: $31,569,000.00Accounts payable → Operating adjustments reconciliation: $22,022,000.00Accrued expenses and other current liabilities → Operating adjustments reconciliation: $9,297,000.00Depreciation and amortization → Operating adjustments reconciliation: $6,590,000.00Amortization of operating lease right-of-use assets → Operating adjustments reconciliation: $4,651,000.00Loss on disposal of property and equipment → Operating adjustments reconciliation: $160,000.00Operating adjustments reconciliation → Net cash from operating activities: $74,046,000.00Operating adjustments reconciliation → Accounts receivable: $20,000,000.00Operating adjustments reconciliation → Prepaid expenses and other assets: $12,013,000.00Operating adjustments reconciliation → Deferred revenue: $8,203,000.00Operating adjustments reconciliation → Net accretion of discount on marketable securities: $4,475,000.00Operating adjustments reconciliation → Operating lease liabilities: $1,161,000.00Proceeds from issuances of common stock in “at the market” financing, net of issuance costs → financing reconciliation: $18,004,000.00Proceeds from exercise of stock options → financing reconciliation: $4,461,000.00Proceeds from issuance of common stock under employee stock purchase plan → financing reconciliation: $2,735,000.00financing reconciliation → Net cash from financing activities: $25,200,000.00Maturities of marketable securities → investing reconciliation: $435,130,000.00investing reconciliation → Net cash from investing activities: $752,000.00investing reconciliation → Purchases of marketable securities: $430,005,000.00investing reconciliation → Purchases of property and equipment: $4,373,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $247,928,000.00Net cash from operating activities → Cash sources and uses: $447,144,000.00Net cash from financing activities → Cash sources and uses: $25,200,000.00Net cash from investing activities → Cash sources and uses: $752,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $721,024,000.00Net income (loss): $373,098,000.00Net income (loss)+$373.10 MDepreciation and amortization: $6,590,000.00Depreciation & amortization+$6.59 MStock-based compensation: $31,569,000.00Stock-based compensation+$31.57 MNet accretion of discount on marketable securities: -$4,475,000.00Investment discount & premium−$4.48 MLoss on disposal of property and equipment: $160,000.00Asset sale gain & loss+$160.00 KAmortization of operating lease right-of-use assets: $4,651,000.00Operating lease amortization+$4.65 MAccounts receivable: -$20,000,000.00Accounts receivable−$20.00 MPrepaid expenses and other assets: -$12,013,000.00Prepaid & other assets−$12.01 MAccounts payable: $22,022,000.00Accounts payable+$22.02 MDeferred revenue: -$8,203,000.00Deferred revenue−$8.20 MOperating lease liabilities: -$1,161,000.00Operating lease liabilities−$1.16 MDeferred collaboration funding: $45,609,000.00Deferred collaboration funding+$45.61 MAccrued expenses and other current liabilities: $9,297,000.00Other payables & accruals+$9.30 MNet cash from operating activities: $447,144,000.00Operating cash+$447.14 MOperating adjustments reconciliation: $119,898,000.00Proceeds from exercise of stock options: $4,461,000.00Stock option exercises+$4.46 MProceeds from issuance of common stock under employee stock purchase plan: $2,735,000.00Employee stock plan proceeds+$2.74 MProceeds from issuances of common stock in “at the market” financing, net of issuance costs: $18,004,000.00Common stock issued+$18.00 MNet cash from financing activities: $25,200,000.00Financing cash+$25.20 Mfinancing reconciliation: $25,200,000.00Purchases of marketable securities: -$430,005,000.00Marketable securities purchases−$430.01 MMaturities of marketable securities: $435,130,000.00Investment sales & maturities+$435.13 MPurchases of property and equipment: -$4,373,000.00PP&E purchases−$4.37 MNet cash from investing activities: $752,000.00Investing cash+$752.00 Kinvesting reconciliation: $435,130,000.00Cash sources and uses: $721,024,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $247,928,000.00Beginning cash$247.93 MEnding cash: Cash, cash equivalents, and restricted cash: $721,024,000.00Ending cash$721.02 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow$442.77 MOperating cash − cash spent on PP&ECash flow / Net income1.20×Operating cash flow ÷ net incomeNet cash change+$473.10 MEnding cash − beginning cash
Chart details

NURIX THERAPEUTICS, INC. cash flow reconciliation, Dec 1, 2025 through Aug 31, 2026

Cash flows for Dec 1, 2025 through Aug 31, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Nov 30, 2025. Ending cash: Aug 31, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Nov 30, 2025
247,928,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
447,144,000 US dollars. Net cash provided.
Net income (loss)
373,098,000 US dollars
Depreciation and amortization
6,590,000 US dollars
Stock-based compensation
31,569,000 US dollars
Net accretion of discount on marketable securities
negative 4,475,000 US dollars
Loss on disposal of property and equipment
160,000 US dollars
Amortization of operating lease right-of-use assets
4,651,000 US dollars
Accounts receivable
negative 20,000,000 US dollars
Prepaid expenses and other assets
negative 12,013,000 US dollars
Accounts payable
22,022,000 US dollars
Deferred revenue
negative 8,203,000 US dollars
Operating lease liabilities
negative 1,161,000 US dollars
Deferred collaboration funding
45,609,000 US dollars
Accrued expenses and other current liabilities
9,297,000 US dollars
Investing activities
752,000 US dollars. Net cash provided.
Purchases of marketable securities
negative 430,005,000 US dollars
Maturities of marketable securities
435,130,000 US dollars
Purchases of property and equipment
negative 4,373,000 US dollars
Financing activities
25,200,000 US dollars. Net cash provided.
Proceeds from exercise of stock options
4,461,000 US dollars
Proceeds from issuance of common stock under employee stock purchase plan
2,735,000 US dollars
Proceeds from issuances of common stock in “at the market” financing, net of issuance costs
18,004,000 US dollars
Operating adjustment reconciliation
119,898,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
25,200,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
435,130,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Aug 31, 2026
721,024,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
721,024,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
473,096,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
1.20×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
447,144,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
4,373,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
442,771,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $74.05M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 447,144,000 US dollars minus 4,373,000 US dollars equals 442,771,000 US dollars.
NURIX THERAPEUTICS, INC. (NRIX) FY2026 YTD Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!